Is TEVA up or down today?
TEVA is up 0.93% today, last at 40.32. This stock moved +0.93% versus the prior close.
TEVA · TEVA
TEVA (TEVA) is trading at 40.32, up 0.93% on the session. TEVA carries a 14-day RSI of 55, and trades above its 50-day average. Over the past month it is up 3.11%.
Leading the coverage: “Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial” (Yahoo, 6d ago). TEVA is -1.08% since story.
TEVA trades on a trailing P/E of 65.7 and is running 3.30% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
TEVA is up 0.93% today, last at 40.32. This stock moved +0.93% versus the prior close.
Leading the coverage: “Sanofi & Teva’s IBD drug prompts long-term clinical remission in Phase IIb trial” (Yahoo, 6d ago). TEVA is -1.08% since story. Dominant story: Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin - Pharmaceutical Executive (1 source, bearish) RSI is 55 — neutral Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Apr 2026 – Oct 2026 (125 days) · Drag or scroll left for earlier dates
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin - Pharmaceutical Executive
Fourteen brokerages set USD 46.08 target for Teva stock - ad-hoc-news.de
Teva Pharmaceutical Industries Unit Buys Rights to BXCL501 From BioXcel Therapeutics
Teva Pharmaceutical Industries (TEVA) Expected to Release Quarterly Earnings on Tuesday - MarketBeat
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline